FORM 4
--------

Г

#### UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response... 0.5

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Typ	e Responses)			-										
1. Name and Address of Reporting Person <sup>*</sup> HUNT RONALD				2. Issuer Name Iterum Theraj			nbol		5. Relationsh	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _X_Director10% Owner				
(Last) (First) (Middle) C/O ITERUM THERAPEUTICS PLC, BLK 2, FL. 3, HARCOURT CENTRE, HARCOURT ST.			3. Date of Earlie 07/01/2020	on (N	/onth/Day	/Year)		Officer (gi	ive title below)	Other (	specify below)			
(Street)				4. If Amendmen	inal I	Filed(Month	/Day/Year)	)	_X_ Form filed b	6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting Person				
DUBLIN, L2 2 (City) (State) (Zip)					Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned									
1.Title of Se (Instr. 3)	ecurity		2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	(Instr. 8)		4. Securi (A) or D (Instr. 3, Amount	isposed of	of (D)	5. Amount of Sec Beneficially Own Reported Transac (Instr. 3 and 4)	ned Followir	6. Ownersh Form: Direct (D or Indirec (I) (Instr. 4)		ial hip
Ordinary	Shares		07/01/2020		М		5,703	А	(1)	5,703		D		
Ordinary	Shares									1,071,688		Ι	By New Ventur L.P. (2)	res III,
Ordinary	Shares									384,615		Ι	By Nev Biopha Opport II, L.P.	arma tunities
Reminder: R	eport on a se	parate line for	each class of securit	ies beneficially own	ned directly	Pe co	ersons w ontained	in this	form a	to the collectior are not required tly valid OMB co	l to respon	nd unless the	SEC 147	74 (9-02)
			Table II	- Derivative Secu (e.g., puts, calls,										
1. Title of Derivative Security (Instr. 3)	2. 3. Transaction 3A. Deemed 4. 5. Number			6. I and	6. Date Exercisable 7. Title and Expiration Date of Und (Month/Day/Year) Securit			Title and Amount Underlying		Derivative Securities Beneficially Owned	Form of	11. Nature of Indirect Beneficial Ownership (Instr. 4)		

					of (	tr. 3, 4,						Transaction(s)	or Indirect (I) (Instr. 4)	
			Code	v	(A)		Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Restricted Stock Units	<u>(1)</u>	07/01/2020	М			5,703	<u>(4)</u>	<u>(4)</u>	Ordinary Shares	5,703	\$ 0	0	D	

## **Reporting Owners**

	Relationships							
Reporting Owner Name / Address		10% Owner	Officer	Other				
HUNT RONALD C/O ITERUM THERAPEUTICS PLC, BLK 2 FL. 3, HARCOURT CENTRE, HARCOURT ST. DUBLIN, L2 2	Х							

### Signatures

Ronald M. Hunt	07/02/2020
Signature of Reporting Person	Date

# **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Restricted stock units converted into ordinary shares on a one-for-one basis upon vesting of the units.

These shares are held directly by New Leaf Ventures III, L.P. ("NLV-III"). New Leaf Venture Associates III, L.P. ("NLVA-III LP") is the general partner of NLV-III and New Leaf Venture Management III, L.L.C. ("NLVM-III LLC") is the general partner of NLVA-III LP, and each of NLVA-III LP and NLVM-III LLC may be deemed to have sole voting,
(2) investment and dispositive power with respect to the shares held by NLV-III. The reporting person, a member of the Issuer's Board of Directors, is a managing director of NLVM-III LLC and, in his capacity as a managing director, may be deemed to have shared voting, investment and dispositive power with respect to the shares held by NLV-III.

Person disclaims Section 16 beneficial ownership of the securities held by NLV-III, except to the extent of his pecuniary interest therein, if any. These shares are held directly by New Leaf Biopharma Opportunities II, L.P. ("NBPO-II"). New Leaf BPO Associates II, L.P. ("NBPO-IIA") is the general partner of NBPO-II and New Leaf BPO Management II, L.L.C. ("NBPO-IIM") is the general partner of NBPO-IIA, and each of NBPO-IIA and NBPO-IIM may be deemed to have sole voting, investment

- (3) and dispositive power with respect to the shares held by NBPO-II. The reporting person, a member of the Issuer's Board of Directors, is a managing director of NBPO-IIM and, in his capacity as a managing director, may be deemed to have shared voting, investment and dispositive power with respect to the shares held by NBPO-II. The Reporting Person disclaims Section 16 beneficial ownership of the securities held by NBPO-II, except to the extent of his pecuniary interest therein, if any.
- (4) On June 13, 2019, the reporting person was granted an award of 5,703 restricted stock units, which vested on July 1, 2020.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.